Dr. Martens (LON:DOCS) Stock Price Down 12.4% – Here’s Why

Dr. Martens plc (LON:DOCS)’s stock price traded down 12.4% during trading on Tuesday . The stock traded as low as GBX 65 and last traded at GBX 66.30. 4,229,807 shares changed hands during trading, an increase of 138% from the average session volume of 1,776,838 shares. The stock had previously closed at GBX 75.65.

Key Headlines Impacting Dr. Martens

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Reducing discounting to protect margins — Management plans to scale back promotions and markdowns, which should help gross margins and underpin profitability if sell‑through holds. Dr Martens projects flat 2026 revenue as it scales back discounts
• Neutral Sentiment: Balance‑sheet and valuation snapshot — DOCS has a market cap ~£638m, a PE around 38.9, quick ratio ~1.13 and current ratio ~2.85; leverage (debt/equity ~127) and a beta ~0.11 suggest limited market sensitivity but meaningful financial leverage to monitor.
• Negative Sentiment: Flat 2026 revenue guidance — Management’s explicit guidance for flat revenue signals a pause in top‑line growth and is being read as cautious for demand and near‑term momentum. Dr Martens projects flat 2026 revenue as it scales back discounts
• Negative Sentiment: Market reaction and technicals — Shares are trading down today and sit below both the 50‑day (GBX 76.53) and 200‑day (GBX 83.47) moving averages, indicating recent selling pressure and a weaker short‑term trend.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on DOCS shares. Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a report on Thursday, November 27th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of GBX 6,000.

Dr. Martens Price Performance

The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The company has a market capitalization of £640.83 million, a PE ratio of 39.00, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The stock’s 50 day simple moving average is GBX 76.53 and its 200-day simple moving average is GBX 83.47.

Dr. Martens (LON:DOCS) last posted its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. As a group, equities analysts forecast that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Insider Buying and Selling at Dr. Martens

In related news, insider Robert Hanson acquired 96,000 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was purchased at an average cost of GBX 79 per share, for a total transaction of £75,840. Over the last three months, insiders have purchased 97,130 shares of company stock worth $7,673,816. Company insiders own 2.79% of the company’s stock.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.